• 1. Evidence of pre-micellar aggregates in aqueous solution of amphiphilic PDMS–PEO block copolymer?
  Domenico Lombardo,Gianmarco Munaò,Pietro Calandra,Luigi Pasqua,Maria Teresa Caccamo Phys. Chem. Chem. Phys., 2019,21, 11983-11991
• 2. Enantiomorphic symmetry breaking in crystallization of molten sodium chlorate?
  Martin R. Ward,Gary W. Copeland,Andrew J. Alexander Chem. Commun., 2010,46, 7634-7636
• 3. Excellent energy storage performance in NaNbO3-based relaxor antiferroeic ceramics under a low electric field
  XuxinCheng,XiaomingChen,PengyuanFan
• 4. Exceptionally high temperature spin crossover in amide-functionalised 2,6-bis(pyrazol-1-yl)pyridine iron(ii) complex revealed by variable temperature Raman spectroscopy and single crystal X-ray diffraction?
  Max Attwood,Hiroki Akutsu,Lee Martin,Toby J. Blundell,Pierre Le Maguere,Scott S. Turner Dalton Trans., 2021,50, 11843-11851
• 5. Excellent electrochemical performance of LiFe0.4Mn0.6PO4 microspheres produced using a double carbon coating process?
  Yong Ping Huang,Tao Tao,Zheng Chen,Wei Han,Ying Wu,Chunjiang Kuang,Shaoxiong Zhou,Ying Chen J. Mater. Chem. A, 2014,2, 18831-18837

Chemical Profile of 1-(3-BROMOPHENYL)-2-PENTANOL (CAS No: 158526-75-1)

1-(3-BROMOPHENYL)-2-PENTANOL, identified by its Chemical Abstracts Service (CAS) number 158526-75-1, is a significant compound in the realm of organic chemistry and pharmaceutical research. This molecule, featuring a brominated phenyl ring and a secondary pentanol substituent, has garnered attention due to its versatile structural properties and potential applications in synthetic chemistry and drug development.

The molecular structure of 1-(3-BROMOPHENYL)-2-PENTANOL consists of a phenyl ring substituted at the 3-position with a bromine atom, linked to a pentyl chain with an alcohol functional group at the 2-position. This configuration imparts unique reactivity, making it a valuable intermediate in the synthesis of more complex molecules. The presence of both a bromine atom and an alcohol group allows for diverse chemical transformations, including nucleophilic aromatic substitution, Suzuki-Miyaura cross-coupling, and oxidation reactions.

In recent years, the pharmaceutical industry has shown increasing interest in halogenated aromatic compounds due to their role as key building blocks in drug discovery. 1-(3-BROMOPHENYL)-2-PENTANOL exemplifies this trend, as its structural features are conducive to the development of novel therapeutic agents. For instance, the bromine substituent can be readily displaced by various nucleophiles, enabling the introduction of diverse functional groups that may enhance drug efficacy or target specificity.

One of the most compelling applications of 1-(3-BROMOPHENYL)-2-PENTANOL lies in its utility as a precursor in the synthesis of biologically active compounds. Researchers have leveraged this molecule to develop inhibitors targeting various enzymatic pathways. Notably, studies have explored its derivatives as potential modulators of kinases and other protein kinases, which are implicated in numerous diseases, including cancer and inflammatory disorders. The alcohol moiety provides a handle for further derivatization, allowing chemists to fine-tune physicochemical properties such as solubility and metabolic stability.

The bromine atom at the 3-position of the phenyl ring is particularly noteworthy, as it serves as a versatile handle for cross-coupling reactions. These reactions are cornerstone techniques in modern synthetic organic chemistry, enabling the formation of carbon-carbon bonds under mild conditions. For example, palladium-catalyzed Suzuki-Miyaura cross-coupling has been employed to introduce aryl or heteroaryl groups adjacent to the bromine substituent. Such transformations have been instrumental in generating libraries of substituted phenols with potential pharmacological activity.

Recent advancements in medicinal chemistry have highlighted the importance of polyhalogenated aromatic compounds in drug design. 1-(3-BROMOPHENYL)-2-PENTANOL, with its dual halogenation (bromine at position 3), offers an attractive scaffold for exploring structure-activity relationships (SAR). By systematically modifying the molecule through functional group interconversions, researchers can dissect how different structural features influence biological outcomes. This approach has yielded promising candidates for further preclinical evaluation.

The synthesis of 1-(3-BROMOPHENYL)-2-PENTANOL itself presents an interesting challenge for organic chemists. While several synthetic routes have been reported, optimizing yield and purity remains crucial for industrial-scale production. Common methodologies involve bromination of pre-formed phenyl-pentyl ethers or direct alkylation strategies involving Grignard reagents or organolithium intermediates. Each route has its advantages and limitations, depending on factors such as cost-effectiveness and scalability.

In addition to its pharmaceutical applications, 1-(3-BROMOPHENYL)-2-PENTANOL has found utility in materials science research. The combination of aromaticity and aliphatic chains makes it a candidate for developing liquid crystals or organic semiconductors. Researchers have investigated its derivatives as components in organic light-emitting diodes (OLEDs) and photovoltaic cells, where precise control over molecular packing is essential for optimal performance.

The environmental impact of halogenated compounds is another critical consideration in their development and use. While brominated molecules offer numerous synthetic advantages, their fate post-synthesis must be carefully managed to minimize ecological footprint. Advances in green chemistry have prompted efforts to develop more sustainable synthetic routes for 1-(3-BROMOPHENYL)-2-PENTANOL, including catalytic methods that reduce waste generation and energy consumption.

Looking ahead, the future prospects for 1-(3-BROMOPHENYL)-2-PENTANOL appear promising, driven by ongoing research into novel therapeutic interventions and advanced materials. As drug discovery continues to evolve toward more targeted and personalized medicine, compounds like this will remain indispensable tools for medicinal chemists seeking to innovate at the molecular level. Collaborative efforts between academia and industry will be essential to translate laboratory findings into tangible benefits for patients worldwide.

• 171965-24-5((2S)-6-bromo-1,2,3,4-tetrahydronaphthalen-2-ol)
• 173996-27-5(6-Bromo-1,2,3,4-tetrahydronaphthalen-2-ol)
• 1249732-28-2(3-bromo-α-ethyl-Benzenepropanol)
• 1283620-13-2(4-(3-bromophenyl)butan-2-ol)
• 2227797-74-0((2R)-1-(3-bromo-5-methylphenyl)propan-2-ol)
• 1184574-05-7(1-(3-BROMOPHENYL)-2-PROPANOL)
• 1179509-17-1(1-(3-Bromophenyl)-2-butanol)
• 141819-15-0(1-(4-BROMOPHENYL)-2-PENTANOL)
• 1780552-87-5(7-bromo-1,2,3,4-tetrahydronaphthalen-2-ol)
• 223554-16-3(4-(4-Bromophenyl)butan-2-ol)